We recently compiled a list of the 12 NASDAQ Stocks with Biggest Upside Potential According to Analysts. In this article, we are going to take a look at where Structure Therapeutics Inc. (NASDAQ:GPCR) ...

The Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamic activity of ACCG-2671 in both healthy volunteers and individuals with obesity. The study will ...

The average one-year price target for Structure Therapeutics Inc. - Depositary Receipt (NasdaqGM:GPCR) has been revised to $94.31 / share. This is an increase of 21.89% from the prior estimate of $77.

Fintel reports that on December 12, 2025, Citizens maintained coverage of Structure Therapeutics Inc. - Depositary Receipt ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2023 investor letter. A copy of the same can be downloaded here. The fund advanced 7.69% ...

Scientists reveal how G protein-coupled receptors, major therapeutic drug targets, decode critical properties of their ligands. Through an international collaboration, scientists at St. Jude ...

Shares of Structure Therapeutics Inc. (NASDAQ: GPCR) are soaring Monday after the clinical-stage biopharmaceutical company reported positive topline data from a weight loss drug trial. The positive ...

Investors with a lot of money to spend have taken a bullish stance on Structure Therapeutics (NASDAQ:GPCR). And retail traders should know. We noticed this today when the trades showed up on publicly ...

Through an international collaboration, scientists at St. Jude Children’s Research Hospital leveraged data science, pharmacology and structural information to conduct an atomic-level investigation ...